Oncopeptides AB
STO:ONCO

Watchlist Manager
Oncopeptides AB Logo
Oncopeptides AB
STO:ONCO
Watchlist
Price: 5.75 SEK -4.17% Market Closed
Market Cap: 1.2B SEK

Net Margin
Oncopeptides AB

-696.7%
Current
-1 368%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-696.7%
=
Net Income
-277.6m
/
Revenue
39.8m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
SE
Oncopeptides AB
STO:ONCO
1.2B SEK
-697%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
333B USD
7%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 848%
US
Amgen Inc
NASDAQ:AMGN
162B USD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
140.7B USD
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.4B USD
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
131.6B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.4B USD
32%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Oncopeptides AB
Glance View

Market Cap
1.2B SEK
Industry
Biotechnology

Oncopeptides AB is a pharmaceutical company focused on the development of targeted therapies for hematological diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2017-02-22. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.

ONCO Intrinsic Value
2.73 SEK
Overvaluation 53%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-696.7%
=
Net Income
-277.6m
/
Revenue
39.8m
What is the Net Margin of Oncopeptides AB?

Based on Oncopeptides AB's most recent financial statements, the company has Net Margin of -696.7%.

Back to Top